Medical Virology of Hepatitis B: how it began and where we are now

Virology Journal

Wolfram H Gerlich¹ 

[1] Institute for Medical Virology, National Reference Center for Hepatitis B and D, Justus Liebig University Giessen, Schubert Str. 81, 35392, Giessen, Germany

关键词: HCC;    Vaccine;    Anti-HBs;    Anti-HBc;    HBsAg;    Hepadnavirus;    Hepatitis B virus;   

Others  :  1149149
DOI  :  10.1186/1743-422X-10-239

 received in 2013-07-08, accepted in 2013-07-18,  发布年份 2013

【 摘 要 】

Infection with hepatitis B virus (HBV) may lead to acute or chronic hepatitis. HBV infections were previously much more frequent but there are still 240 million chronic HBV carriers today and ca. 620,000 die per year from the late sequelae liver cirrhosis or hepatocellular carcinoma. Hepatitis B was recognized as a disease in ancient times, but its etiologic agent was only recently identified. The first clue in unraveling this mystery was the discovery of an enigmatic serum protein named Australia antigen 50 years ago by Baruch Blumberg. Some years later this was recognized to be the HBV surface antigen (HBsAg). Detection of HBsAg allowed for the first time screening of inapparently infected blood donors for a dangerous pathogen. The need to diagnose clinically silent HBV infections was a strong driving force in the development of modern virus diagnostics. HBsAg was the first infection marker to be assayed with a highly sensitive radio immune assay. HBV itself was among the first viruses to be detected by assay of its DNA genome and IgM antibodies against the HBV core antigen were the first to be selectively detected by the anti-μ capture assay. The cloning and sequencing of the HBV genome in 1978 paved the way to understand the viral life cycle, and allowed development of efficient vaccines and drugs. Today’s hepatitis B vaccine was the first vaccine produced by gene technology. Among the problems that still remain today are the inability to achieve a complete cure of chronic HBV infections, the recognition of occult HBV infections, their potential reactivation and the incomplete protection against escape mutants and heterologous HBV genotypes by HBV vaccines.

【 授权许可】

   
2013 Gerlich; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

Figure 9.

【 参考文献 】

• [1]Blumberg BS: Hepatitis B - The hunt for a killer virus. Princeton: Princeton University Press; 2002.
• [2]Lürmann A: Eine Icterusepidemie. Ber Klin Wochenschr. 1885, 22:20-23.
• [3]MacCallum FO: 1971 International symposium on viral hepatitis. Historical perspectives. Can Med Assoc J 1972, 106(Suppl):423-426.
• [4]Seeff LB, Beebe GW, Hoofnagle JH, Norman JE, Buskell-Bales Z, Waggoner JG, Kaplowitz N, Koff RS, Petrini JL Jr, Schiff ER, et al.: A serologic follow-up of the 1942 epidemic of post-vaccination hepatitis in the United States Army. N Engl J Med. 1987, 316:965-970.
• [5]Barker LF, Murray R: Relationship of virus dose to incubation time of clinical hepatitis and time of appearance of hepatitis–associated antigen. Am J Med Sci 1972, 263:27-33.
• [6]Krugman S, Giles JP, Hammond J: Infectious hepatitis. Evidence for two distinctive clinical, epidemiological, and immunological types of infection. JAMA 1967, 200:365-373.
• [7]Prince AM: Relation of Australia and SH antigens. Lancet 1968, 2(7565):462-463.
• [8]Ling CM, Overby LR: Prevalence of hepatitis B virus antigen as revealed by direct radioimmune assay with 125 I-antibody. J Immunol 1972, 109:834-841.
• [9]Le Bouvier GL, McCollum RW, Hierholzer WJ Jr, Irwin GR, Krugman S, Giles JP: Subtypes of Australia antigen and hepatitis-B virus. JAMA 1972, 222:928-930.
• [10]Bancroft WH, Mundon FK, Russell PK: Detection of additional antigenic determinants of hepatitis B antigen. J Immunol 1972, 109:842-848.
• [11]Millman I, Loeb LA, Bayer ME, Blumberg BS: Australia antigen (a hepatitis-associated antigen): purification and physical properties. J Exp Med 1970, 131:1190-1199.
• [12]Gerlich W, May G: Hepatitis-associated antigen: purification and properties. Zentralbl Bakteriol Orig A 1973, 224:49-60. German
• [13]Griffith JS: Self-replication and scrapie. Nature 1967, 215:1043-1044.
• [14]Dane DS, Cameron CH, Briggs M: Virus-like particles in serum of patients with Australia-antigen-associated hepatitis. Lancet 1970, 1(7649):695-698.
• [15]Almeida JD, Rubenstein D, Stott EJ: New antigen-antibody system in Australia-antigen-positive hepatitis. Lancet 1971, 2(7736):1225-1227.
• [16]Seitz S, Urban S, Antoni C, Böttcher B: Cryo-electron microscopy of hepatitis B virions reveals variability in envelope capsid interactions. EMBO J 2007, 26:4160-4167.
• [17]Hirschman SZ, Vernace SJ, Schaffner F: D.N.A. polymerase in preparations containing Australia antigen. Lancet 1971, 1(7709):1099-1103.
• [18]Kaplan PM, Greenman RL, Gerin JL, Purcell RH, Robinson WS: DNA polymerase associated with human hepatitis B antigen. J Virol 1973, 12:995-1005.
• [19]Robinson WS, Clayton DA, Greenman RL: DNA of a human hepatitis B virus candidate. J Virol 1974, 14:384-391.
• [20]Berg P, Baltimore D, Brenner S, Roblin RO, Singer MF: Summary statement of the Asilomar conference on recombinant DNA molecules. Proc Natl Acad Sci USA 1975, 72:1981-1984.
• [21]Charnay P, Pourcel C, Louise A, Fritsch A, Tiollais P: Cloning in Escherichia coli and physical structure of hepatitis B virion DNA. Proc Natl Acad Sci USA 1979, 76:2222-2226.
• [22]Valenzuela P, Gray P, Quiroga M, Zaldivar J, Goodman HM, Rutter WJ: Nucleotide sequence of the gene coding for the major protein of hepatitis B virus surface antigen. Nature 1979, 280:815-819.
• [23]Pasek M, Goto T, Gilbert W, Zink B, Schaller H, MacKay P, Leadbetter G, Murray K: Hepatitis B virus genes and their expression in E. coli. Nature 1979, 282:575-579.
• [24]Wittkop L, Schwarz A, Cassany A, Grün-Bernhard S, Delaleau M, Rabe B, Cazenave C, Gerlich W, Glebe D, Kann M: Inhibition of protein kinase C phosphorylation of hepatitis B virus capsids inhibits virion formation and causes intracellular capsid accumulation. Cell Microbiol 2010, 12:962-975.
• [25]Will H, Cattaneo R, Koch HG, Darai G, Schaller H, Schellekens H, van Eerd PM, Deinhardt F: Cloned HBV DNA causes hepatitis in chimpanzees. Nature 1982, 299:740-742.
• [26]Hoofnagle JH, Gerety RJ, Barker LF: Antibody to hepatitis-B-virus core in man. Lancet 1973, 2(7834):869-873.
• [27]Hoofnagle JH, Seeff LB, Bales ZB, Zimmerman HJ: Type B hepatitis after transfusion with blood containing antibody to hepatitis B core antigen. N Engl J Med 1978, 298:1379-1383.
• [28]Galbraith RM, Eddleston AL, Williams R, Zuckerman AJ: Fulminant hepatic failure in leukaemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy. Lancet 1975, 2(7934):528-530.
• [29]Flehmig B, Ranke M, Berthold H, Gerth HJ: A solid-phase radioimmunoassay for detection of IgM antibodies to hepatitis A virus. J Infect Dis 1979, 140:169-175.
• [30]Gerlich WH, Lüer W: Selective detection of IgM-antibody against core antigen of the hepatitis B virus by a modified enzyme immune assay. J Med Virol 1979, 4:227-238.
• [31]Gerlich WH, Uy A, Lambrecht F, Thomssen R: Cutoff levels of immunoglobulin M antibody against viral core antigen for differentiation of acute, chronic, and past hepatitis B virus infections. J Clin Microbiol 1986, 24:288-293.
• [32]Milich DR, McLachlan A: The nucleocapsid of hepatitis B virus is both a T-cell-independent and a T-cell-dependent antigen. Science 1986, 234:1398-1401.
• [33]Magnius LO, Espmark A: A new antigen complex co-occurring with Australia antigen. Acta Pathol Microbiol Scand B Microbiol Immunol 1972, 80:335-337.
• [34]Standring DN, Ou JH, Masiarz FR, Rutter WJ: A signal peptide encoded within the precore region of hepatitis B virus directs the secretion of a heterogeneous population of e antigens in Xenopus oocytes. Proc Natl Acad Sci USA 1988, 85:8405-8409.
• [35]Bruss V, Gerlich WH: Formation of transmembraneous hepatitis B e-antigen by cotranslational in vitro processing of the viral precore protein. Virology 1988, 163:268-275.
• [36]Carman WF, Jacyna MR, Hadziyannis S, Karayiannis P, McGarvey MJ, Makris A, Thomas HC: Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989, 2(8663):588-591.
• [37]Milich DR, Chen MK, Hughes JL, Jones JE: The secreted hepatitis B precore antigen can modulate the immune response to the nucleocapsid: a mechanism for persistence. J Immunol 1998, 160:2013-2021.
• [38]Maynard JE, Berquist KR, Krushak DH, Purcell RH: Experimental infection of chimpanzees with the virus of hepatitis B. Nature 1972, 237:514-515.
• [39]Petersen J, Dandri M, Gupta S, Rogler CE: Liver repopulation with xenogenic hepatocytes in B and T cell-deficient mice leads to chronic hepadnavirus infection and clonal growth of hepatocellular carcinoma. Proc Natl Acad Sci USA 1998, 95:310-315.
• [40]Köck J, Nassal M, MacNelly S, Baumert TF, Blum HE, von Weizsäcker F: Efficient infection of primary tupaia hepatocytes with purified human and woolly monkey hepatitis B virus. J Virol 2001, 75:5084-5089.
• [41]Glebe D, Urban S, Knoop EV, Çag N, Krass P, Grün S, Bulavaite A, Sasnauskas K, Gerlich WH: Mapping of the hepatitis B virus attachment site by infection-inhibiting preS1 lipopeptides using Tupaia hepatocytes. Gastroenterology 2005, 129:234-245.
• [42]Gripon P, Rumin S, Urban S, Le Seyec J, Glaise D, Cannie I, Guyomard C, Lucas J, Trepo C, Guguen-Guillouzo C: Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci USA 2002, 99:15655-15660.
• [43]Quint WG, Heijtink RA, Schirm J, Gerlich WH, Niesters HG: Reliability of methods for hepatitis B virus DNA detection. J Clin Microbiol 1995, 33:225-228.
• [44]Gerlich WH, Robinson WS: Hepatitis B virus contains protein attached to the 5’ terminus of its complete DNA strand. Cell 1980, 21:801-809.
• [45]Saldanha J, Gerlich W, Lelie N, Dawson P, Heermann K, Heath A, WHO Collaborative Study Group: An international collaborative study to establish a World Health Organization international standard for hepatitis B virus DNA nucleic acid amplification techniques. Vox Sang 2001, 80:63-71.
• [46]Tabuchi A, Tanaka J, Katayama K, Mizui M, Matsukura H, Yugi H, Shimada T, Miyakawa Y, Yoshizawa H: Titration of hepatitis B virus infectivity in the sera of pre-acute and late acute phases of HBV infection: transmission experiments to chimeric mice with human liver repopulated hepatocytes. J Med Virol 2008, 80:2064-2068.
• [47]Allain JP, Mihaljevic I, Gonzalez-Fraile MI, Gubbe K, Holm-Harritshøj L, Garcia JM, Brojer E, Erikstrup C, Saniewski M, Wernish L, Bianco L, Ullum H, Candotti D, Lelie N, Gerlich WH, Chudy M: Infectivity of blood products from donors with occult hepatitis B virus infection. Transfusion 2013. doi: 10.1111/trf.12096. [Epub ahead of print]
• [48]Gunson RN, Shouval D, Roggendorf M, Zaaijer H, Nicholas H, Holzmann H, de Schryver A, Reynders D, Connell J, Gerlich WH, Marinho RT, Tsantoulas D, Rigopoulou E, Rosenheim M, Valla D, Puro V, Struwe J, Tedder R, Aitken C, Alter M, Schalm SW, Carman WF, European Consensus Group: Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections in health care workers (HCWs): guidelines for prevention of transmission of HBV and HCV from HCW to patients. J Clin Virol 2003, 27:213-230.
• [49]Couroucé-Pauty AM, Soulier JP: Further data on HBs antigen subtypes - geographical distribution. Vox Sang 1974, 27:533-549.
• [50]Okamoto H, Tsuda F, Sakugawa H, Sastrosoewignjo RI, Imai M, Miyakawa Y, Mayumi M: Typing hepatitis B virus by homology in nucleotide sequence: comparison of surface antigen subtypes. J Gen Virol 1988, 69:2575-2583.
• [51]Norder H, Couroucé AM, Coursaget P, Echevarria JM, Lee SD, Mushahwar IK, Robertson BH, Locarnini S, Magnius LO: Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervirology 2004, 47:289-309.
• [52]Andernach IE, Nolte C, Pape JW, Muller CP: Slave trade and hepatitis B virus genotypes and subgenotypes in Haiti and Africa. Emerg Infect Dis 2009, 15:1222-1228.
• [53]Kramvis A, Kew MC: Molecular characterization of subgenotype A1 (subgroup Aa) of hepatitis B virus. Hepatol Res 2007, 37(Suppl 1):S27-S32.
• [54]Davies J, Littlejohn M, Locarnini SA, Whiting S, Hajkowicz K, Cowie BC, Bowden DS, Tong SY, Davis JS: The molecular epidemiology of Hepatitis B in the Indigenous people of northern Australia. J Gastroenterol Hepatol 2013. [Epub ahead of print]
• [55]Paraskevis D, Magiorkinis G, Magiorkinis E, Ho SY, Belshaw R, Allain JP, Hatzakis A: Dating the origin and dispersal of hepatitis B virus infection in humans and primates. Hepatology 2013, 57:908-916.
• [56]Shi W, Zhu C, Zheng W, Zheng W, Ling C, et al.: Subgenotyping of genotype C hepatitis B virus: correcting misclassifications and identifying a novel subgenotype. PLoS ONE 2012, 7(10):e47271.
• [57]Mason WS, Gerlich WH, Taylor JM, Kann M, Loeb D, Sureau S, Magnius L, Norder H: Family Hepadnaviridae. Amsterdam: Elsevier; 2012:445-455. [Virus taxonomy, ninth report of the international committee on taxonomy of viruses]
• [58]Lanford RE, Chavez D, Brasky KM, Burns RB 3rd, Rico-Hesse R: Isolation of a hepadnavirus from the woolly monkey, a new world primate. Proc Natl Acad Sci USA 1998, 95:5757-5761.
• [59]Dreesman JM, Baillot A, Hamschmidt L, Monazahian M, Wend UC, Gerlich WH: Outbreak of hepatitis B in a nursing home associated with capillary blood sampling. Epidemiol. Infect 2006, 26:1102-1113.
• [60]Guidotti LG, Chisari FV: Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol. 2006, 1:23-61.
• [61]Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, Colombo M, Craxì A, Donato F, Ferrari C, Gaeta GB, Gerlich WH, Levrero M, Locarnini S, Michalak T, Mondelli MU, Pawlotsky JM, Pollicino T, Prati D, Puoti M, Samuel D, Shouval D, Smedile A, Squadrito G, Trépo C, Villa E, Will H, Zanetti AR, Zoulim F: Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 2008, 49:652-657.
• [62]Westhoff TH, Jochimsen F, Schmittel A, Stöffler-Meilicke M, Schäfer JH, Zidek W, Gerlich WH, Thiel E: Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood 1930, 2003:102.
• [63]Blaich A, Manz M, Dumoulin A, Schüttler CG, Hirsch HH, Gerlich WH, Frei R: Reactivation of hepatitis B virus with mutated HBsAg in a liver transplant recipient receiving a graft from an anti-HBs and anti-HBc positive donor. Transfusion 2012, 52:1999-2006.
• [64]Turelli P, Mangeat B, Jost S, Vianin S, Trono D: Inhibition of hepatitis B virus replication by APOBEC3G. Science 2004, 303:1829.
• [65]Szmuness W: Hepatocellular carcinoma and the hepatitis B virus: evidence for a causal association. Prog Med Virol 1978, 24:40-69.
• [66]Beasley RP, Hwang LY, Lin CC, Chien CS: Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet 1981, 2(8256):1129-1133.
• [67]Alexander JJ, Bey EM, Geddes EW, Lecatsas G: Establishment of a continuously growing cell line from primary carcinoma of the liver. S Afr Med J 1976, 50:2124-2128.
• [68]Edman JC, Gray P, Valenzuela P, Rall LB, Rutter WJ: Integration of hepatitis B virus sequences and their expression in a human hepatoma cell. Nature 1980, 286:535-538.
• [69]Kekulé AS, Lauer U, Meyer M, Caselmann WH, Hofschneider PH, Koshy R: The preS2/S region of integrated hepatitis B virus DNA encodes a transcriptional transactivator. Nature 1990, 343:457-461.
• [70]Höhne M, Schaefer S, Seifer M, Feitelson MA, Paul D, Gerlich WH: Malignant transformation of immortalized transgenic hepatocytes after transfection with hepatitis B virus DNA. EMBO Journal 1990, 9:1137-1145.
• [71]Lucifora J, Arzberger S, Durantel D, Belloni L, Strubin M, Levrero M, Zoulim F, Hantz O, Protzer U: Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection. J Hepatol 2011, 55:996-1003.
• [72]Dejean A, Bougueleret L, Grzeschik KH, Tiollais P: Hepatitis B virus DNA integration in a sequence homologous to v-erb-A and steroid receptor genes in a hepatocellular carcinoma. Nature 1986, 322:70-72.
• [73]Mason WS, Liu C, Aldrich CE, Litwin S, Yeh MM: Clonal expansion of normal-appearing human hepatocytes during chronic hepatitis B virus infection. J Virol 2010, 84:8308-8315.
• [74]Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH: REVEAL-HBV Study Group: Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006, 295:65-73.
• [75]Summers J, Smolec JM, Snyder R: A virus similar to human hepatitis B virus associated with hepatitis and hepatoma in woodchucks. Proc Natl Acad Sci USA 1978, 75:4533-4537.
• [76]Marion PL, Oshiro LS, Regnery DC, Scullard GH, Robinson WS: A virus in Beechey ground squirrels that is related to hepatitis B virus of humans. Proc Natl Acad Sci USA 1980, 77:2941-2945.
• [77]Fourel G, Trepo C, Bougueleret L, Henglein B, Ponzetto A, Tiollais P, Buendia MA: Frequent activation of N-myc genes by hepadnavirus insertion in woodchuck liver tumours. Nature 1990, 347:294-298.
• [78]Mason WS, Seal G, Summers J: Virus of Pekin ducks with structural and biological relatedness to human hepatitis B virus. J Virol 1980, 36:829-836.
• [79]Sprengel R, Kaleta EF, Will H: Isolation and characterization of a hepatitis B virus endemic in herons. J Virol 1988, 62:3832-3839.
• [80]Suh A, Brosius J, Schmitz J, Kriegs JO: The genome of a mesozoic paleovirus reveals the evolution of hepatitis B viruses. Nature Communications 2013, 4:1791.
• [81]Summers J, Mason WS: Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate. Cell 1982, 29:403-415.
• [82]Nassal M: Hepatitis B viruses: reverse transcription a different way. Virus Res 2008, 134:235-249.
• [83]Rabe B, Vlachou A, Panté N, Helenius A, Kann M: Nuclear import of hepatitis B virus capsids and release of the viral genome. Proc Natl Acad Sci USA 2003, 100:9849-9854.
• [84]Gerelsaikhan T, Tavis JE, Bruss V: Hepatitis B virus nucleocapsid envelopment does not occur without genomic DNA synthesis. J Virol 1996, 70:4269-4274.
• [85]Bruss V, Lu X, Thomssen R, Gerlich WH: Post-translational alterations in transmembrane topology of the hepatitis B virus large envelope protein. EMBO J 1994, 13:2273-2279.
• [86]Lambert C, Döring T, Prange R: Hepatitis B virus maturation is sensitive to functional inhibition of ESCRT-III, Vps4, and gamma 2-adaptin. J Virol 2007, 81:9050-9060.
• [87]Sells MA, Chen ML, Acs G: Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. Proc Natl Acad Sci USA 1987, 84:1005-1009.
• [88]Zahn P, Allain JP: Hepatitis C virus and hepatitis B virus bind to heparin: purification of largely IgG-free virions from infected plasma by heparin chromatography. J Gen Virol 2005, 86:677-685.
• [89]Sureau C, Salisse J: A conformational heparan sulfate binding site essential to infectivity overlaps with the conserved hepatitis B virus a-determinant. Hepatology 2013, 57:985-994.
• [90]Heermann KH, Goldmann U, Schwartz W, Seyffarth T, Baumgarten H, Gerlich WH: Large surface proteins of hepatitis B virus containing the pre-s sequence. J Virol 1984, 52:396-402.
• [91]Neurath AR, Kent SB, Strick N, Parker K: Identification and chemical synthesis of a host cell receptor binding site on hepatitis B virus. Cell 1986, 46:429-436.
• [92]Ishikawa T, Ganem D: The pre-S domain of the large viral envelope protein determines host range in avian hepatitis B viruses. Proc Natl Acad Sci USA 1995, 92:6259-6263.
• [93]Eng FJ, Novikova EG, Kuroki K, Ganem D, Fricker LD: Gp180, a protein that binds duck hepatitis B virus particles, has metallocarboxypeptidase D-like enzymatic activity. J Biol Chem 1998, 273:8382-8388.
• [94]Glebe D, Aliakbari M, Krass P, Knoop EV, Valerius KP, Gerlich WH: Pre-s1 antigen-dependent infection of Tupaia hepatocyte cultures with human hepatitis B virus. J Virol 2003, 77:9511-9521.
• [95]Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z, Huang Y, Qi Y, Peng B, Wang H, Fu L, Song M, Chen P, Gao W, Ren B, Sun Y, Cai T, Feng X, Sui J, Li W: Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife 2012, 1:e00049.
• [96]Greenberg HB, Pollard RB, Lutwick LI, Gregory PB, Robinson WS, Merigan TC: Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis. N Engl J Med 1976, 295:517-522.
• [97]Petersen J, Buti M: Considerations for the long-term treatment of chronic hepatitis B with nucleos(t)ide analogs. Expert Rev Gastroenterol Hepato. 2012, 6:683-693.
• [98]Gerlich W, Stamm B, Thomssen R: Prognostic significance of quantitative HBsAg determination in acute hepatitis B. Partial report of a cooperative clinical study of the DFG-focus of “virus hepatitis”. Verh Dtsch Ges Inn Med 1977, 83:554-557. German
• [99]Doong SL, Tsai CH, Schinazi RF, Liotta DC, Cheng YC: Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues. Proc Natl Acad Sci USA 1991, 88:8495-8499.
• [100]Benhamou Y, Dohin E, Lunel-Fabiani F, Poynard T, Huraux JM, Katlama C, Opolon P, Gentilini M: Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients. Lancet 1995, 345(8946):396-397.
• [101]Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M: A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995, 333:1657-1661.
• [102]Torresi J, Locarnini S: Antiviral chemotherapy for the treatment of hepatitis B virus infections. Gastroenterology 2000, 118(Suppl 1):S83-S103.
• [103]Warner N, Locarnini S: The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatology 2008, 48:88-98.
• [104]van Bömmel F, Wünsche T, Mauss S, Reinke P, Bergk A, Schürmann D, Wiedenmann B, Berg T: Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 2004, 40:1421-1425.
• [105]Han GR, Cao MK, Zhao W, Jiang HX, Wang CM, Bai SF, Yue X, Wang GJ, Tang X, Fang ZX: A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. J Hepatol 2011, 55:1215-1221.
• [106]Volz T, Allweiss L, Barek MB M, Warlich M, Lohse AW, Pollok JM, Alexandrov A, Urban S, Petersen J, Lütgehetmann M, Dandri M: The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. J Hepatol 2013, 58:861-867.
• [107]Kosinska AD, Zhang E, Johrden L, Liu J, Seiz PL, Zhang X, Ma Z, Kemper T, Fiedler M, Glebe D, Wildner O, Dittmer U, Lu M, Roggendorf M: Combination of DNA prime - adenovirus boost immunization with entecavir elicits sustained control of chronic hepatitis B in the woodchuck model. PLoS Pathog 2013, 9:e1003391.
• [108]Beasley RP, Hwang LY, Lin CC, Stevens CE, Wang KY, Sun TS, Hsieh FJ, Szmuness W: Hepatitis B immune globulin (HBIG) efficacy in the interruption of perinatal transmission of hepatitis B virus carrier state. Initial report of a randomised double-blind placebo-controlled trial. Lancet 1981, 2(8243):388-393.
• [109]Krugman S, Giles JP, Hammond J: Viral hepatitis, type B (MS-2 strain). Studies on active immunization. JAMA 1971, 217:41-45.
• [110]Purcell RH, Gerin JL: Hepatitis B subunit vaccine: a preliminary report of safety and efficacy tests in chimpanzees. Am J Med Sci 1975, 270:395-399.
• [111]Maupas P, Goudeau A, Coursaget P, Drucker J, Bagros P: Immunisation against hepatitis B in man. Lancet 1976, 1(7974):1367-1370.
• [112]Szmuness W, Stevens CE, Harley EJ, Zang EA, Oleszko WR, William DC, Sadovsky R, Morrison JM, Kellner A: Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med 1980, 303:833-841.
• [113]Peterson DL, Roberts IM, Vyas GN: Partial amino acid sequence of two major component polypeptides of hepatitis B surface antigen. Proc Natl Acad Sci USA 1977, 74:1530-1534.
• [114]Valenzuela P, Medina A, Rutter WJ, Ammerer G, Hall BD: Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. Nature 1982, 298:347-350.
• [115]Harford N, Cabezon T, Crabeel M, Simoen E, Rutgers A, De Wilde M: Expression of hepatitis B surface antigen in yeast. Dev Biol Stand 1983, 54:125-130.
• [116]McAleer WJ, Buynak EB, Maigetter RZ, Wampler DE, Miller WJ, Hilleman MR: Human hepatitis B vaccine from recombinant yeast. Nature 1984, 307:178-180.
• [117]Poovorawan Y, Sanpavat S, Pongpunlert W, Chumdermpadetsuk S, Sentrakul P, Safary A: Protective efficacy of a recombinant DNA hepatitis B vaccine in neonates of HBe antigen-positive mothers. JAMA 1989, 261:3278-3281.
• [118]Lavanchy D: Viral hepatitis: global goals for vaccination. J Clin Virol 2012, 55:296-302.
• [119]Chang MH, You SL, Chen CJ, Liu CJ, Lee CM, Lin SM, Chu HC, Wu TC, Yang SS, Kuo HS, Chen DS, Taiwan Hepatoma Study Group: Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst 2009, 101:1348-1355.
• [120]Su WJ, Liu CC, Liu DP, Chen SF, Huang JJ, Chan TC, Chang MH: Effect of age on the incidence of acute hepatitis B after 25 years of a universal newborn hepatitis B immunization program in Taiwan. J Infect Dis 2012, 205:757-762.
• [121]Poovorawan Y, Chongsrisawat V, Theamboonlers A, Leroux-Roels G, Kuriyakose S, Leyssen M, Jacquet J-M: Evidence of protection against clinical and chronic hepatitis B infection 20 years after infant vaccination in a high endemicity region. J Viral Hepat 2011, 18:369-375.
• [122]Coates T, Wilson R, Patrick G, André F, Watson V: Hepatitis B vaccines: assessment of the seroprotective efficacy of two recombinant DNA vaccines. Clin Ther 2001, 23:392-403.
• [123]Wolters B, Junge U, Dziuba S, Roggendorf M: Immunogenicity of combined hepatitis A and B vaccine in elderly persons. Vaccine. 2003, 21:3623-3628.
• [124]Hsu HY, Chang MH, Ni YH, Chiang CL, Chen HL, Wu JF, Chen PJ: No increase in prevalence of hepatitis B surface antigen mutant in a population of children and adolescents who were fully covered by universal infant immunization. J Infect Dis 2010, 201:1192-1200.
• [125]Stramer SL, Wend U, Candotti D, Foster GA, Hollinger FB, Dodd RY, Allain J-P, Gerlich W: Nucleic acid testing to detect HBV infection in blood donors. New Engl J Med 2011, 364:236-247.
• [126]Feeney SA, McCaughey C, Watt AP, El Agnaf MR, McDougal N, Morris K, Wend UC, Gerlich WH, Coyle PV: Reactivation of occult hepatitis B virus infection following cytotoxic lymphoma therapy in an anti-HBc negative patient. J Med Virol 2013, 85:597-601.
• [127]Bremer CM, Sominskaya I, Skrastina D, Pumpens P, El Wahed AA, Beutling U, Frank R, Fritz HJ, Hunsmann G, Gerlich WH, Glebe D: N-terminal myristoylation-dependent masking of neutralizing epitopes in the preS1 attachment site of hepatitis B virus. J Hepatol 2011, 55:29-37.
• [128]Chen D-S: Toward elimination and eradication of hepatitis B. J Gastroenterol Hepatol 2010, 25:11-25.
• [129]Zuckerman JN, Zuckerman AJ: Recombinant hepatitis B triple antigen vaccine: Hepacare. Expert Rev Vaccines 2002, 1:141-144.
• [130]Shouval D: Hepatitis B, vaccines. J Hepatol 2003, 39(Suppl 1):S70-S76.
• [131]Rendi-Wagner P, Shouval D, Genton B, Lurie Y, Rümke H, Boland G, Cerny A, Heim M, Bach D, Schroeder M, Kollaritsch H: Comparative immunogenicity of a PreS/S hepatitis B vaccine in non- and low responders to conventional vaccine. Vaccine 2006, 24:2781-2789.
• [132]Niedre-Otomere B, Bogdanova A, Skrastina D, Zajakina A, Bruvere R, Ose V, Gerlich WH, Garoff H, Pumpens P, Glebe D, Kozlovska T: Recombinant Semliki forest virus vectors encoding hepatitis B virus small surface and pre-S1 antigens induce broadly reactive neutralizing antibodies. J Viral Hepatitis 2012, 19:664-673.